1. Home
  2. CISO vs SCYX Comparison

CISO vs SCYX Comparison

Compare CISO & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CISO Global Inc.

CISO

CISO Global Inc.

HOLD

Current Price

$0.46

Market Cap

24.5M

Sector

Technology

ML Signal

HOLD

Logo SCYNEXIS Inc.

SCYX

SCYNEXIS Inc.

HOLD

Current Price

$0.64

Market Cap

24.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CISO
SCYX
Founded
2015
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
24.5M
24.6M
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
CISO
SCYX
Price
$0.46
$0.64
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$3.00
AVG Volume (30 Days)
817.2K
506.3K
Earning Date
11-13-2025
11-05-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$27,743,266.00
$2,932,000.00
Revenue This Year
N/A
$167.73
Revenue Next Year
N/A
$290.78
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.30
$0.57
52 Week High
$3.84
$1.49

Technical Indicators

Market Signals
Indicator
CISO
SCYX
Relative Strength Index (RSI) 30.24 42.20
Support Level $0.46 $0.63
Resistance Level $0.60 $0.67
Average True Range (ATR) 0.06 0.03
MACD 0.01 0.00
Stochastic Oscillator 3.33 10.26

Price Performance

Historical Comparison
CISO
SCYX

About CISO CISO Global Inc.

CISO Global Inc provides cybersecurity services. The services are used to protect client's data, financial information, intellectual property, and business reputation. The services include penetration testing, security remediation, compliance auditing, vulnerability assessment, and others. Geographically, the company operates in U.S., Chile and All other countries. The maximum revenue is generated from U.S.

About SCYX SCYNEXIS Inc.

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

Share on Social Networks: